Patents Assigned to Novartis AG
  • Solid forms comprising an oxime ether compound, compositions and methods of use thereof
    Patent number: 11958805
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 16, 2024
    Assignee: NOVARTIS AG
    Inventors: Lianfeng Huang, Daozhong Zou
  • BCMA chimeric antigen receptors and uses thereof
    Patent number: 11952428
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: April 9, 2024
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
    Patent number: 11952386
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
    Patent number: 11951190
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Methods of using factor B inhibitors
    Patent number: 11951101
    Abstract: Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: April 9, 2024
    Assignee: Novartis AG
    Inventors: Irina Baltcheva, Peter End, Julie Marie-Pomme Gabrielle Milojevic
  • Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
    Patent number: 11944602
    Abstract: The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: April 2, 2024
    Assignee: NOVARTIS AG
    Inventors: Eric Legangneux, Alexandros Sagkriotis, Pierre Jordaan, Florine Polus, Alan John Camm, Shibadas Biswal, Parasar Pal, Uday Kiran Veldandi, Atul Keshav Pawar, Vassilios Aslanis, Kasra Shakeri-Nejad
  • Protein solution formulation containing high concentration of an anti-VEGF antibody
    Patent number: 11945859
    Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: April 2, 2024
    Assignee: NOVARTIS AG
    Inventors: Juergen Sigg, Pamela De Moor
  • Fibroblast growth factor-21-Fc fusion proteins
    Patent number: 11944664
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: April 2, 2024
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • BCMA chimeric antigen receptors and uses thereof
    Patent number: 11939389
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: March 26, 2024
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
    Patent number: 11939397
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: March 26, 2024
    Assignee: Novartis AG
    Inventors: Michael Didonato, Christoph Erkel, Anna Galkin, Scott Glaser, Klaus Felix Hartlepp, Yong Jia, Alexandra Kraus, Christian Cho-Hua Lee, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler
  • Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
    Patent number: 11931430
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Antibody-cytokine engrafted proteins and methods of use for immune related disorders
    Patent number: 11930837
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
  • Triazolopyrimidine compounds and uses thereof
    Patent number: 11931363
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • Hepatitis B antibodies
    Patent number: 11932681
    Abstract: The present invention relates to anti-HBsAg antibodies, antibody fragments, and their uses for the prevention and treatment of hepatitis B virus infection and associated diseases.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: March 19, 2024
    Assignee: Novartis AG
    Inventors: Stefan Ewert, Meghan Marie Holdorf, Elisabetta Traggiai
  • USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER
    Publication number: 20240082215
    Abstract: The present invention relates to the use of mavoglurant in the treatment of gambling disorder. The present invention also relates to the use of mavoglurant in the treatment of gaming disorder.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 14, 2024
    Applicants: Novartis AG, Yale University
    Inventors: Fabrizio GASPARINI, Baltazar GOMEZ-MANCILLA, John KRYSTAL, Vincent MALATERRE, Stephanie O'MALLEY, Godfrey PEARLSON, Marc POTENZA
  • Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
    Patent number: 11919946
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: March 5, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Michael C. Milone, Enxiu Wang
  • Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators
    Patent number: 11919911
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: March 5, 2024
    Assignee: Novartis AG
    Inventors: Sung David C. Kim, Zaixing Li, Chui Lu, Danuta Lubicka, James Neef, Hye-Yeon Park, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • Pyridine and pyrazine derivative for the treatment of chronic bronchitis
    Patent number: 11911371
    Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: February 27, 2024
    Assignee: NOVARTIS AG
    Inventors: Urs Baettig, Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Glyn Alan Hughes, Darren Mark Le Grand, Katrin Spiegel
  • Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
    Patent number: 11912715
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: February 27, 2024
    Assignee: Novartis AG
    Inventors: Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, James Clifford Sutton, Benjamin R. Taft, Lifeng Wan, Aregahegn Yifru, Qian Zhao
  • Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
    Patent number: RE49847
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: February 27, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes, Saar Gill, Marco Ruella, Regina M. Young